Medical Science Liaison of the Year has been expanded to include three levels of seniority and forms the backbone of the all new Medical and Scientific Excellence Awards, alongside categories for scientific advisors and medical information professionals.
ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
Alarm bells over the NHS’ ability to cope with looming winter pressures are ringing again after some aspects of service performance sunk to new lows in the summer, with record waiting times for A&E and cancer treatment.
The biggest ever trial for secondary progressive multiple sclerosis (SPMS) has kicked off in the UK at around 30 sites in England, Scotland, Wales, Northern Ireland and Eire.
AstraZeneca and its biologics R&D arm MedImmune have bagged US approval of Lumoxiti for the treatment of hairy cell leukaemia (HCL), marking the first new treatment option in 20 years.
Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics.
The number of people visiting A&E in England has jumped by more than one-fifth in ten years, official figures show.
Gilead and Precision BioSciences are to work together on developing gene-editing treatments against hepatitis B.
The Department of Health in Northern Ireland has unveiled plans to boost access to innovative new medicines for cancers and other conditions.
Entry to the 2018 PharmaTimes Marketer of the Year competition will close on Friday 14 September.
The highly prestigious PharmaTimes Communications Team of the Year competition will close for entry at midnight on Friday. Take this opportunity to compete alongside other healthcare agencies in a one-off challenge to shape real-life solutions for one of the UK’s leading charities.
Gilead and Galapagos have unveiled another set of promising data for JAK inhibitor filgotinib, this time in rheumatoid arthritis.
MSD is gearing up to file antibiotic Zerbaxa on both sides of the Atlantic for certain forms of pneumonia on the success of a late-stage trial backing its safety and efficacy.
The production of new cell and gene therapies at a manufacturing site in Stevenage – for use in health services around the world – has been given the green light by the Medicines and Healthcare products Regulatory Agency (MHRA).
Merck KGaA and Pfizer say they intend to seek US approval of a combination of Bavencio and Inlyta for kidney cancer on the back of progression-free survival data from a late-stage trial.
